TYVASO DPI IS NOW APPROVED

Skip to main content

For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

Skip to main content

PREVALENCE

PH may be present in patients at any stage of ILD1

PH is sometimes present even at initial diagnosis1

Up to 15% of patients with IPF also have signs of PH in early stages of disease or at diagnosis.1

Why regularly assess for PH-ILD?

Because as ILD advances, frequency of PH continues to rise.1

For example, in patients with advanced and end-stage IPF, prevalence of PH can rise beyond 50%1*

At each visit, the patient’s ILD may have progressed, making it more likely that they will start to show signs of PH-ILD.1

Uncover PH-ILD early by screening at diagnosis of ILD, as well as regularly screening ILD patients at follow-up visits. 

*In IPF, the extent of restriction does not correlate with mPAP.2

 

ILD=interstitial lung disease; IPF=idiopathic pulmonary fibrosis; mPAP=mean pulmonary arterial pressure; PH=pulmonary hypertension.